{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '6.5.8.', 'Adverse Events', 'All subjects will be monitored for adverse events (AEs) during the study. Assessments may', \"include monitoring of any or all of the following parameters: the subject's clinical symptoms,\", 'laboratory, radiological, or surgical findings; physical examination findings; psychiatric', 'evaluation; or other appropriate tests and procedures.', 'All AEs will be recorded by the Investigator from the time the subject signs informed consent to', '28 days after the last dose of IP. Adverse events and serious adverse events (SAEs) will be', 'recorded on the AE page of the electronic case report form (eCRF), the paper SAE reporting', \"form (SAEs) and in the subject's source documents. All SAEs must be reported to Amgen\", \"Global Patient Safety within 24 hours of the Investigator's knowledge of the event by recording\", 'on the CRF and using the paper Serious Adverse Event Report Form by facsimile/email of the', 'paper SAER Form directly to Amgen Global Patient Safety.', 'Details of AE reporting can be found in Section 10.1 of the protocol.', 'Confidential and Proprietary', '40', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '7.', 'DESCRIPTION OF STUDY TREATMENTS', '7.1.', 'Description of Investigational Product(s)', 'The chemical name of apremilast (CC-10004) is acetamide, N-[2-[(1S)-1-(3-ethoxy-e', 'methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl].', 'Apremilast will be provided by Amgen as 10, 20, or 30 mg tablets in blister cards for dose', 'titration purposes. Apremilast will also be provided as 30 mg tablets in high-density polyethylene', '(HDPE) bottles (approximately 80 tablets) with child-resistant caps.', 'Identically-appearing placebo tablets will also be provided by Amgen in blister cards.', '7.2.', 'Treatment Administration and Schedule', 'Subjects will be dispensed blister cards with 10, 20, and 30 mg apremilast tablets, or identically', 'appearing placebo, for the dose titration, at the baseline visit (Week 0) and Week 16.', 'Starting at Week 16, all subjects will be switched to, or will continue with, apremilast. Subjects', 'originally randomized to placebo at Week 0 will be switched to apremilast at Week 16. At all', 'visits (Week 0 to Week 16), titration / treatment will be dispensed in blister cards with apremilast', 'or placebo tablets and will be identically appearing. Beginning with the Week 20 visit, all', 'subjects will receive open label HDPE bottles of IP tablets. All subjects will maintain this', 'dosing through Week 52.', 'Apremilast or placebo tablets will be taken orally twice daily, approximately 12 hours apart,', 'through the last treatment visit.', 'The titration blister card configurations are pictured in Appendix R. The treatment schema for', 'dose titration at Baseline is shown in Appendix P, and at Week 16 is shown in Appendix Q.', 'Dose modifications are not permissible in this study.', '7.3.', 'Method of Treatment Assignment', 'After the informed consent is signed, subjects will be assigned a subject identification number', 'using a centralized interactive response technology (IRT). At the Baseline Visit, a centralized', 'schema will be applied to assign subjects who meet the eligibility criteria in a 2:1 ratio to receive', 'either apremilast 30 mg tablets orally BID or identically-appearing placebo tablets using the IRT.', 'Subjects will be block-randomized to each of the manifestations of plaque psoriasis specified in', 'the protocol. If subjects present with multiple manifestations, they will be allocated to the', 'manifestation which is most severe, as determined by the subject at the screening and baseline', 'visits. However, all manifestations will be assessed for efficacy at each study visit.', 'Designated research personnel at the investigational sites will be assigned password protected,', 'coded identification numbers, which gives them authorization to enter the IRT to randomize', 'subjects. The system will present a menu of questions by which the research center personnel', 'will identify the subject and confirm subject eligibility. When all questions have been answered', 'and the subject deemed eligible, the IRT will assign a randomization identification number.', 'Confirmation of the randomization will be sent to the investigational site, Amgen, and/or its', 'representative. The confirmation reports should be maintained as source documents. During the', 'Confidential and Proprietary', '41', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'study visits, the pharmacy or authorized study personnel at the investigational site will dispense', 'coded IP kits in accordance with the randomization number assigned by the IRT.', '7.4.', 'Packaging and Labeling', 'The label(s) for IP will include Sponsor name, address and telephone number, the protocol', 'number, IP name, dosage form and strength (where applicable), amount of IP per container, lot', 'number, expiry date (where applicable), medication identification/kit number, dosing', 'instructions, storage conditions, and required caution statements and/or regulatory statements as', 'applicable. Additional information may be included on the label as applicable per local', 'regulations.', 'All IP tablets, including apremilast and identically-appearing placebo, will be supplied by', 'Amgen. Investigational product for dose titration at Baseline and to Week 20 will be supplied in', 'blister cards. Investigational product tablets at Week 20 and through Week 52 will be supplied in', 'open label HDPE bottles with child-resistant caps.', '7.5.', 'Investigational Product Accountability and Disposal', 'The Investigator, or designee, is responsible for taking an inventory of each shipment of oral IP', 'received, and comparing it with the accompanying IP shipping order/packing list.', 'The Investigator, or designee, will verify the accuracy of the information on the form, sign and', 'date it, retain a copy in the study file, and record the information in the IRT..', 'Investigational product will be stored per the storage conditions identified on the IP label. At the', 'study site, all IP will be stored in a locked, safe area to prevent unauthorized access.', 'Amgen (or designee) will review with the Investigator and relevant site personnel the process for', 'IP return, disposal, and/or destruction including responsibilities for the site versus Amgen (or', 'designee).', '7.6.', 'Investigational Product Compliance', 'Study personnel will review the instructions printed on the package with the study subjects prior', 'to dispensing the IP in tablet form (both blister cards and bottles). Investigational product will be', 'dispensed as noted in the Table of Events, Table 3. The subjects will be instructed to return the', 'IP containers, including any unused medication, to the study site at each visit for tablet counts', 'and reconciliation. At each study visit, subjects will be asked whether they have taken their IP as', 'instructed. Any problems with IP compliance will be reviewed with the subject. If a subject', 'misses 4 or more consecutive days of dosing, Amgen should be contacted to decide whether', 'dosing should resume or whether the subject should be terminated from the Treatment Phase of', 'the study, and enter into the Posttreatment Observational Follow-up Phase.', 'Gross compliance problems (eg, missing 4 or more consecutive days of dosing or taking less', 'than 75% of the doses between study visits) should be discussed with Amgen. Compliance is', 'defined as taking between 75% and 120% of dispensed IP.', 'Confidential and Proprietary', '42', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}